In this article, we will discuss Golimumab and Pharmacodynamics. So, let’s get started.
Golimumab and Pharmacodynamics
In clinical studies, decreases in C-reactive protein (CRP), interleukin (IL)-6, matrix metalloproteinase 3 (MMP-3), intercellular adhesion molecule (ICAM)-l and vascular endothelial growth factor (VEOF) were observed following Golimumab administration in patients with RA, PsA, and AS.